Abstract
Aim: Lung cancer remains the leading cause of cancer-related deaths worldwide. Number of studies have focused on exploring the efficacy of consolidation chemotherapy (CCT) following concurrent CRT to improve survival. But these studies have discordant results. For patients with LA-NSCLC the efficacy and safety of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is not well defined. Therefore, the aim of this study was to evaluate the efficacy and toxicity of CCT.
Methods: We retrospectively analysed the clinical records of LA-NSCLC patients treated with concurrent CRT as an initial treatment at our Chest Diseases Hospital between January 2010 and January 2014. All patients were cyto-histologically proven NSCLC and clinically diagnosed as stage III according to the American Joint Committee on Cancer (AJCC) 2009 staging system. All patients treated with curative thoracic radiotherapy with concurrent platinum doublet chemotherapy. We investigated the overall survival (OS) and progression-free survival (PFS) on exploring the efficacy of consolidation chemotherapy (CCT) following concurrent CRT to improve survival.
Results: 63 LA-NSCLC patients were participated in the study (6 female, 57 male). The median OS is 18 (95% CI) and the median PFS is 9 (95% CI) months. The detailed datas will be presented during the congress.
- Copyright ©the authors 2016
